Market Overview

Biogen Misses Q1 Estimates, Shares Slide


Shares of Biogen Inc (NASDAQ: BIIB) dropped over 4 percent in pre-market trading after the company reported weaker-than-expected earnings for the first quarter on Friday.

The Cambridge, Massachusetts-based company reported a quarterly profit of $822.5 million, or $3.49 per share, versus a year-ago profit of $480 million, or $2.02 per share. Excluding items, Biogen earned $3.82 per share.

Its revenue surged 20 percent to $2.55 billion. However, analysts were expecting a profit of $3.91 per share on revenue of $2.66 billion.

Tecfidera sales gained 63 percent to $824.9 million in the quarter, while revenue from Tysabri climbed to $462.6 million versus $441 million. ELOCTATE revenue came in at $54 million during the quarter, while ALPROLIX revenue came in at $43 million.

The average estimate among 29 Estimize users was for earnings of $4.07 per share and revenue of $2.7 billion.

"In the first quarter, we continued to gain share in the MS market and we believe that our MS product portfolio is well positioned to provide patients the breadth of choices that they need," said Chief Executive Officer George A. Scangos, Ph.D. "While we saw moderating patient growth of our oral MS therapy TECFIDERA in the U.S. and Germany, the launch of PLEGRIDY continued to go well, and we have seen continued strong performance from TYSABRI. We believe that our portfolio offers patients leading choices among oral, interferon, and high-efficacy therapies, and we look forward to continued growth in our global market share."

Biogen shares fell 4.48 percent to $411.01 in pre-market trading.

Posted-In: profitEarnings News


Related Articles (BIIB)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at